Please login to the form below

What next for health? The weeks that have seen a whirlwind in Whitehall.

It won’t have escaped your attention that the debris from the PM’s recent reshuffle has left industry and policy makers with more questions than it has answers. This comes at a critical time for the healthcare system, particularly ahead of the winter period. ‘Levelling Up’ is the agenda. Covid has highlighted the extent of health inequalities across the UK. In her latest blog, Ursula Ritz considers the implications of the change of senior leadership at DHSC and NHSE for existing priorities, including for those of us committed to ensuring the best and innovative drugs make it to patients.

Harold Wilson famously quoted that a week is a long time in politics. The PM’s latest reshuffle, Amanda Pritchard’s appointment to NHSE, as well as health policy taking centre stage at the Conservative Party Conference, it leaves one to question whether these radical leadership changesare a wise move at such a critical time for the UK’s healthcare system.

‘Build back better’ – that’s what we’re told is the focus of the administration. Sajid Javid outlined in his inaugural conference speech as Health Secretary that the primary objective for DHSC will be to set health provision back on track post-pandemic, whilst also addressing the startling 13 million patients currently on NHS waiting lists, at the same time warning that things are likely to ‘get worse before they get better’. If you then account for other diagnostic challenges for serious illnesses such as cancer and diabetes, you can be forgiven for thinking there is a particularly long way to go before we reach the pre-pandemic status-quo, which itself wasn’t devoid of long waiting lists and winter pressures.

The Health Secretary’s appointment in June this year came as no surprise to many political commentators, having held a solid track record of working with the PM in previous years as part of EU Exit and with a shared ambition for leadership within the Conservative Party. Javid is known to not shy away from difficult issues, having held some of the most prominent ministerial positions in Whitehall, including those of the Home Secretary and Chancellor in recent years. Whilst still relatively new to the world of healthcare, his tenure commenced with a defiant stand on the lifting of lockdown restrictions over the summer, a decision clearly shared with that of the PM. With two of the most powerful people in the country (seemingly) aligned on how to ‘get the job done’, where does this leave Javid’s ministerial team, as well as the NHS’ senior leadership in the long road to recovery?

NHSE Chief Executive, Amanda Pritchard, will certainly have her (and the wider NHS’) work cut out for them. The Health and Social Care Bill continues to make its way through the legislative mill, promising to deliver on a number of fundamental reforms to the governance and accountability of the organisation, as outlined in the NHS Long Term Plan. To implement such substantial changes at the same time as local and national public services recover from COVID, could be widely seen as an unenviable task, and it seems a substantial amount of hope has been placed on the successful implementation of Integrated Care Systems in order to minimise the risk of a potentially damaging winter period. This will also be Pritchard’s first winter as NHSE Chief and will therefore be under a lot of pressure to work extremely closely with DHSC and Number 10 to keep reputational, policy and political plates spinning as booster jabs, the Bill passage, and resource issues (to name but a few) all heighten in the lead up to 2022.

Whilst the Health and Social Care Bill will see DHSC awarded with a greater degree of scrutiny over NHS management than we have seen for several years, any political point scoring in the media or in Parliament at the NHS’ expense would be unwise. The DHSC ministerial class of 2021 is fresh-faced and will inevitably need to hit the ground running to deliver on NHS Long Term plan promises, with little capacity for diversion from pre-agreed strategies. Javid and Pritchard will need to jointly steer the NHS helm to ensure clear and honest communication is at the apex of healthcare decision making. Actions (and results) will speak louder than words in the language of this government.

So, what does this mean for the rest of us outside of the Westminster bubble?

We must both widen and deepen our understanding of the new NHS landscapeand the political environment in which it operates – both on a local and national level. Levelling Up is a core element of how the government intends to ‘build back better’, and that demands a review of how we as industry leaders can not only inform business and engagement strategies to develop and integrate new therapies from the lab to our hospital wards, but that we ourselves provide the thought leadership and be the voice of what does and doesn’t work in the new world. ICSs have the potential to represent the very best from our communities, and at their core, are based on the spirit of collaboration to create positive outcomes for local people. No matter what is happening in SW1, we must also roll up our sleeves to understand, engage and deliver on core issues facing patients and healthcare providers, and provide those solutions no matter who may be in charge at the helm.

There is no doubt a long winter ahead, but we at Hanover stand ready with you to endure the weather, come rain or shine, together.

11th October 2021

Share

Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

Address:
Riverside House
Southwark Bridge House
London
SE1 9HA
United Kingdom

Latest content on this profile

Femtech: Transforming the future of women's healthcare
Femtech is potentially the most important development in health care right now. Women's health has been under-researched and overlooked for successive generations - it's time that government and industry get ready to deliver.
Hanover Communications
VPAS: The importance of making the right arguments, even in challenging times
With key workers’ strikes, inflation, and immense pressure on public services, arguing for a more generous pricing settlement for the pharmaceuticals industry could not be tougher. Read our Health Director James Mole’s thoughts on the support needed to protect the UK life sciences’ ambitions, despite the challenging backdrop.
Hanover Communications
Putting prevention at the heart of the future of the NHS
Prioritising the prevention of cardiovascular disease (CVD) should be at the heart of plans to safeguard the long-term sustainability of the NHS. Unfortunately, action in this area has to date not matched ambition, putting thousands of patients’ lives – and the future of the health system – at risk.
Hanover Communications
Action on Anti-microbial resistance: Will the UK rise to the challenge
Timely and effective antimicrobials are the cornerstone of our healthcare systems, providing life-saving treatment and supporting vital services like routine operations, transplants and cancer treatment. We are three years into the UK Government’s 20-Year Vision for Antimicrobial Resistance (AMR), and the Department of Health and Social Care recently launched a consultation for the next iteration of the AMR National Action Plan (2024-2029). However, latest figures show that AMR is still on the rise. Is UK policy ambitious enough to drive innovation in AMR, and is the Government on track to contain, control and mitigate AMR by 2040?
Hanover Communications
Winter and workforce woes: challenges facing the new Secretary of State for Health and Social Care
For the third time this year, the NHS and social care has a new Secretary of State. The appointment must now signal stability following a period of political turbulence, as we head into what health leaders are describing as the toughest winter to date. Backlogs, delayed discharges, ambulance and A&E pressures, and crumbling NHS estates will remain top of Steve Barclay’s priority list in the coming weeks and months ahead. However, he will also need to address the longstanding workforce issues that hold back both the NHS and social care sector. Only dealing with these structural challenges will ensure the health and care system is operationally fit for winters to come.
Hanover Communications
A new 10-year cancer plan: Will the government be able to deliver what the sector needs?
The Truss Government has committ­ed to developing a new 10-year cancer plan. But set against the backdrop of the Secretary of States priorities, what real value can the sector expect a new cancer plan to deliver? What questions need addressing to drive impactful change for patients? Will there be funding available to support the transformation?  We will explore the state of play of cancer care in England and assess the main priorities, including how they align with wider NHS challenges. We will set out the difficult choices that a new plan must confront to enable prioritisation of this complex disease area and consider the balance between taking action to impact patients now versus initiatives to benefit patients of the future.
Hanover Communications